0001683168-23-004890.txt : 20230714 0001683168-23-004890.hdr.sgml : 20230714 20230714102811 ACCESSION NUMBER: 0001683168-23-004890 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 33 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230714 DATE AS OF CHANGE: 20230714 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CNBX Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001343009 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203373669 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52403 FILM NUMBER: 231088266 BUSINESS ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 877-424-2429 MAIL ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: Cannabics Pharmaceuticals Inc. DATE OF NAME CHANGE: 20140620 FORMER COMPANY: FORMER CONFORMED NAME: American Mining Corp DATE OF NAME CHANGE: 20110510 FORMER COMPANY: FORMER CONFORMED NAME: Thrust Energy Corp. DATE OF NAME CHANGE: 20051031 10-Q 1 cnbx_i10q-053123.htm QUARTERLY REPORT
0001343009 false --08-31 2023 Q3 0001343009 2022-09-01 2023-05-31 0001343009 2023-07-14 0001343009 2023-05-31 0001343009 2022-08-31 0001343009 2023-03-01 2023-05-31 0001343009 2022-03-01 2022-05-31 0001343009 2021-09-01 2022-05-31 0001343009 us-gaap:CommonStockMember 2022-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001343009 CNBX:WarrantsMember 2022-08-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-08-31 0001343009 us-gaap:RetainedEarningsMember 2022-08-31 0001343009 us-gaap:CommonStockMember 2023-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2023-02-28 0001343009 CNBX:WarrantsMember 2023-02-28 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-02-28 0001343009 us-gaap:RetainedEarningsMember 2023-02-28 0001343009 2023-02-28 0001343009 us-gaap:CommonStockMember 2021-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001343009 CNBX:WarrantsMember 2021-08-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-08-31 0001343009 us-gaap:RetainedEarningsMember 2021-08-31 0001343009 2021-08-31 0001343009 us-gaap:CommonStockMember 2022-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001343009 CNBX:WarrantsMember 2022-02-28 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-02-28 0001343009 us-gaap:RetainedEarningsMember 2022-02-28 0001343009 2022-02-28 0001343009 us-gaap:CommonStockMember 2022-09-01 2023-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-09-01 2023-05-31 0001343009 CNBX:WarrantsMember 2022-09-01 2023-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-09-01 2023-05-31 0001343009 us-gaap:RetainedEarningsMember 2022-09-01 2023-05-31 0001343009 us-gaap:CommonStockMember 2023-03-01 2023-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2023-03-01 2023-05-31 0001343009 CNBX:WarrantsMember 2023-03-01 2023-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-01 2023-05-31 0001343009 us-gaap:RetainedEarningsMember 2023-03-01 2023-05-31 0001343009 us-gaap:CommonStockMember 2021-09-01 2022-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2022-05-31 0001343009 CNBX:WarrantsMember 2021-09-01 2022-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-09-01 2022-05-31 0001343009 us-gaap:RetainedEarningsMember 2021-09-01 2022-05-31 0001343009 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001343009 CNBX:WarrantsMember 2022-03-01 2022-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-01 2022-05-31 0001343009 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001343009 us-gaap:CommonStockMember 2023-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001343009 CNBX:WarrantsMember 2023-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-05-31 0001343009 us-gaap:RetainedEarningsMember 2023-05-31 0001343009 us-gaap:CommonStockMember 2022-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001343009 CNBX:WarrantsMember 2022-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-05-31 0001343009 us-gaap:RetainedEarningsMember 2022-05-31 0001343009 2022-05-31 0001343009 CNBX:TwoDirectorsMember 2022-09-01 2023-05-31 0001343009 CNBX:TwoDirectorsMember 2021-09-01 2022-05-31 0001343009 CNBX:TwoDirectorsMember 2023-05-31 0001343009 CNBX:TwoDirectorsMember 2022-05-31 0001343009 CNBX:YarivAndBaradMember 2023-05-31 0001343009 CNBX:CannabicsMember 2023-05-31 0001343009 CNBX:CannabicsMember 2022-05-31 0001343009 CNBX:ShareBasedPaymentMember CNBX:ChairmanBoardMembersAndAdvisorMember 2022-09-01 2023-05-31 0001343009 CNBX:SubsidiaryMember currency:ILS 2023-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________

 

FORM 10-Q

_______________

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended May 31, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______.

 

Commission File Number: 000-52403

___________________________________________________

 

CNBX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

___________________________________________________

 

Nevada   46-5644005

(State or other jurisdiction of

incorporation or organization)

   (IRS Employer Identification No.)
     

#3 Bethesda Metro Center, Suite 700

Bethesda, MD

   20814
(Address of principal executive offices)   (Zip Code)

 

(877) 424-2429

(Registrant’s telephone number, including area code)

 

 

____________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒  No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒  No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company," and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer  ☐ Accelerated filer  ☐
Non-accelerated filer  ☒ Smaller reporting company  ☒
  Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No  ☒

 

As of July 14, 2023, the registrant had 17,033,732 shares of its Common Stock, $0.0001 par value, outstanding.

 

When used in this quarterly report, the terms “CNBX,” “the Company,” “we,” “our,” and “us” refer to CNBX Pharmaceuticals Inc. and its wholly owned subsidiaries, G.R.I.N Ultra Ltd., and Digestix Bioscience Inc.

 

 

 

   

 

 

CNBX PHARMACEUTICALS INC.

FORM 10-Q

MAY 31ST, 2023

 

INDEX

 

Cautionary Note Regarding Forward-Looking Statements 3
   
PART I – FINANCIAL INFORMATION 4
     
Item 1. Consolidated Financial Statements 4
  Consolidated Balance Sheets as of May 31st, 2023 (unaudited) and August 31, 2022 4
  Consolidated Statements of Operations for the Three and Nine Months Ended May 31st, 2023 and 2022 (unaudited) 5
  Consolidated Statements of Stockholders’ Equity (Deficit) for the Three and Nine Months Ended May 31st, 2023 and 2022 and the Year Ended August 31, 2022 6
  Consolidated Statements of Cash Flows for the Nine Months Ended May 31st, 2023 and 2022 (unaudited) 8
  Notes to Consolidated Financial Statements (unaudited) 9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
Item 3. Quantitative and Qualitative Disclosures About Market Risk 15
Item 4. Controls and Procedures 15
     
PART II -- OTHER INFORMATION 16
Item 1. Legal Proceedings 16
Item 1A. Risk Factors 16
Item 2. Recent Sale of Unregistered Securities 16
Item 6. Exhibits 16
     
SIGNATURES 17

 

 

 

 

 

 2 

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

 

  · the size and growth of the potential markets for our products and the ability to serve those markets;
     
  · our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;
     
  · the rate and degree of market acceptance of any of our products;
     
  · our expectations regarding competition;
     
  · our anticipated growth strategies;
     
  · our ability to attract or retain key personnel;
     
  · our ability to establish and maintain development partnerships;
     
  · regulatory developments in the U.S. and foreign countries, especially those related to change in, and enforcement of, cannabis laws;
     
  · our ability to obtain and maintain intellectual property protection for our products; and
     
  · the anticipated trends and challenges in our business and the market in which we operate.

 

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended August 31, 2022, entitled “Risk Factors” as well as in our other public filings.

 

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

 

 

 

 3 

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

CNBX PHARMACEUTICALS INC.

Consolidated Balance Sheets

 

         
   May 31,   August 31, 
   2023   2022 
   Unaudited   Audited 
ASSETS          
           
Current assets:          
Cash and cash equivalents  $44,151   $117,515 
Prepaid expenses and other receivables   304,645    80,772 
Total current assets   348,796    198,287 
           
Available for sale Investment   –    176,087 
           
Equipment, net   313,223    436,792 
           
Total assets  $662,019   $811,166 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
Current liabilities:          
Accounts payable and accrued liabilities  $1,015,240   $461,128 
Convertible loan   1,332,577    1,758,702 
Due to a related party   223,645    223,645 
Total current liabilities  $2,571,462   $2,443,475 
           
Stockholders' equity (deficit):          
Preferred stock, $0.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding.   –    – 
Common stock, $0.0001 par value, 900,000,000 shares authorized, 16,033,732 shares issued and outstanding at May 31, 2023 and 1,257,927 shares issued and outstanding at August 31, 2022.   1,603    124 
Additional paid-in capital   18,646,026    18,031,869 
Issuance of warrants   3,459,510    3,459,510 
Other comprehensive loss   (330,933)   (2,574,846)
Accumulated deficit   (23,685,648)   (20,548,968)
Total stockholders' equity   (1,909,442)   (1,632,311)
           
Total liabilities and stockholders' equity  $662,019   $811,166 

 

 

See accompanying notes to consolidated financial statements.

 

 

 

 4 

 

 

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

                 
   For the Three Months Ended   For the Nine Months Ended 
   May 31,   May 31,   May 31,   May 31, 
   2023   2022   2023   2022 
   Unaudited 
Revenues  $310,165   $–   $310,165   $– 
                     
Operating expenses:                    
Research and development expense  $263,115   $249,061   $338,330   $1,019,682 
General and administrative expenses   220,132    385,945    741,716    1,455,935 
Total operating expenses   483,247    635,006    1,080,046    2,475,617 
                     
Loss from operations   (173,082)   (635,006)   (769,881)   (2,475,617)
                     
Other income                    
Capital Loss   –    –    (2,395,298)   – 
Financial Income (Loss)   18,392    (46,646)   28,499    (767,926)
Net loss   (154,690)   (681,652)   (3,136,680)   (3,243,543)
                     
Profit (loss) from available for sale assets   –    42,261    (59,870)   (605,740)
Total comprehensive (income) loss  $(154,690)  $(639,392)  $(3,196,550)  $(3,849,283)
                     
Net loss per share - basic  $(0.02)  $(0.05)  $(0.78)  $(2.65)
Net loss per share - diluted  $(0.02)  $(0.05)  $(0.78)  $(2.65)
Weighted average number of shares outstanding - Basic   9,265,865    1,238,826    4,030,048    1,221,478 
Weighted average number of shares outstanding - Diluted   9,265,865    1,238,826    4,030,048    1,221,478 

 

 

See accompanying notes to consolidated financial statements.

 

 

 

 5 

 

 

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Stockholders' Equity (Deficit)

 

                             
   Common stock  

Additional

paid in

       Unrealized gain (loss) on available-for sale financial   Accumulated   Total
stockholders’ equity		 
   Shares   Amount   capital   Warrants   gain   deficit   (deficit) 
Balance, August 31, 2022   1,238,659   $124   $18,031,869   $3,459,510   $(2,574,846)  $(20,548,968)  $(1,632,311)
                                    
Exercise of CLA to shares   14,795,073    1,479    468,652    –    –    –    470,131 
                                    
Share based payment   –    –    145,505    –    –    –    145,505 
                                    
Realization of available for sale asset   –    –    –    –    2,243,913    –    2,243,913 
                                    
Net loss   –    –    –    –    –    (3,136,680)   (3,136,680)
                                    
Balance, May 31, 2023   16,033,732   $1,603   $18,646,026   $3,459,510   $(330,933)  $(23,685,648)  $(1,909,442)

 

 

 

   Common stock  

Additional

paid in

       Unrealized gain (loss) on available-for sale financial   Accumulated   Total
stockholders’ equity		 
   Shares   Amount   capital   Warrants   gain   deficit   (deficit) 
Balance, February 28, 2023   2,190,138   $222   $18,390,628   $3,459,510   $(330,933)  $(23,530,958)  $(2,011,531)
                                    
Exercise of CLA to shares   13,843,594    1,381    220,423    –    –    –    221,804 
                                    
Share based payment   –    –    34,975    –    –    –    34,975 
                                    
Net Loss   –    –    –    –    –    (154,690)   (154,690)
                                    
Balance, May 31, 2023   16,033,732   $1,603   $18,646,026   $3,459,510   $(330,933)  $(23,685,648)  $(1,909,442)

 

 

 

 6 

 

 

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Stockholders' Equity (Deficit)

(continued)

 

                                   
   Common stock  

Additional

paid in

       Unrealized gain (loss) on available-for sale financial   Accumulated   Total
stockholders’ equity		 
   Shares   Amount   capital   Warrants   gain   deficit   (deficit) 
Balance, August 31, 2021   1,218,799   $122   $17,077,715   $3,459,510   $(1,905,715)  $(16,825,718)  $1,805,914 
                                    
Exercise of CLA to shares   20,027    2    225,287    –    –    –    225,289 
                                    
Share based payment   –    –    635,587    –    –    –    635,587 
                                    
Other comprehensive loss   –    –    –    –    (605,740)   –    (605,740)
                                    
Net loss   –    –    –    –    –    (3,243,543)   (3,243,543)
                                    
Balance, May 31, 2022   1,238,826   $124   $17,938,589   $3,459,510   $(2,511,455)  $(20,069,261)  $(1,182,493)

 

 

 

                                   
   Common stock  

Additional

paid in

       Unrealized gain (loss) on available-for sale financial   Accumulated   Total
stockholders’ equity		 
   Shares   Amount   capital   Warrants   gain   deficit   (deficit) 
Balance, February 28, 2022   1,238,826   $124   $17,833,663   $3,459,510   $(2,553,716)  $(19,387,609)  $(648,028)
                                    
Share based payment   –    –    104,926    –    –    –    104,926 
                                    
Other comprehensive gain   –    –    –    –    42,261    –    42,261 
                                    
Net Loss   –    –    –    –    –    (681,652)   (681,652)
                                    
Balance, May 31, 2022   1,238,826   $124   $17,938,589   $3,459,510   $(2,511,455)  $(20,069,261)  $(1,182,493)

 

 

See accompanying notes to consolidated financial statements.

 

 

 

 7 

 

 

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Cash Flows

(Unaudited)

 

         
   For the nine months ended, 
   May 31,   May 31, 
   2023   2022 
Cash flows from operating activities:          
Net Loss  $(3,136,680)  $(3,243,543)
Adjustments required to reconcile net loss to net cash used in operating activities:          
Depreciation   123,569    151,239 
Interest on loans   –    – 
Capital Gain   2,395,298    – 
Due to related party   –    – 
Royalties receivables valuation   –    – 
Stock issued for services   –    – 
Profit from held for trading investments   –    – 
Convertible loan valuation   9,033    718,392 
Share based payment   145,505    635,587 
Changes in operating assets and liabilities:          
Accounts Receivable and pre paid expenses   (223,873)   66,560 
Accounts payable and accrued liabilities   554,110    142,083 
Net cash used in operating activities   (133,038)   (1,529,682)
           
Cash flows from investing activities:          
Proceeds from sale of available for sale investments   24,702    – 
Held for trading investments   –    – 
Acquisition of equipment   –    (513)
Net cash gain in investing activities   24,702    (513)
           
Cash flows from financing activities:          
Convertible loan   34,972    240,000 
Proceeds from sale of common stock   –    – 
Costs of raising capital   –    – 
Net cash provided by financing activities   34,972    240,000 
           
Effect of exchange rate fluctuations on cash   –    – 
Net decrease in cash   (73,364)   (1,290,195)
Cash and cash equivalents at beginning of the Period   117,515    1,386,472 
Cash and cash equivalents at end of the Period  $44,151   $96,277 
           
Significant non-cash transactions:          
Exercise of a Convertible loan to shares of common stock.  $470,131   $225,287 

 

See accompanying notes to consolidated financial statements.

 

 

 

 8 

 

 

CNBX PHARMACEUTICALS INC.

Notes to Consolidated Financial Statements

(Unaudited)

 

 

Note 1 – Nature of Business, Presentation and Going Concern

 

Organization

 

CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.

 

On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.

 

On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, CNBX Pharmaceuticals Inc. purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.

 

On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.

 

On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.

 

On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.

 

On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.

 

On August 20th, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including in-vivo experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.

  

On February 13th, 2022, the company established a Nomination and Governance Committee.

 

 

 

 9 

 

 

On May 10, 2022, the Company filed a certificate of change (the “Certificate”) with the Secretary of State of the State of Nevada. Pursuant to the Certificate, the Company effectuated a one-for-one hundred twenty (1:120) reverse split of the issued and outstanding shares of common stock of the Company without changing the par value of the stock.

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

These unaudited financial statements should be read in conjunction with our August 31, 2022 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 30th, 2022.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiaries GRIN Ultra and Digestix Bioscience Inc. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Going Concern

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $3,136,680 for the nine months ended May 31st, 2023, it has incurred cumulative losses since inception of $23,685,648. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

 

Research and Development Costs

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $338,330 and $1,019,682 for the nine months ended May 31st, 2023 and 2022, respectively.

 

Reclassifications

 

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.

 

 

 

 10 

 

 

Note 2 – Related Party Transactions

 

During the nine months ending May 31st, 2023, the Company paid $7,000 in salaries, including socials benefits, to two directors, compared to $264,061 for the nine months ending May 31, 2022.

 

During the nine months ending May 31st, 2023 the Company accrued $334,658 in salaries, including socials benefits, to two directors compared to $115,039 for the nine months ending May 31, 2022.

 

As of May 31, 2023, the Company had a balance outstanding payable to two directors: Gabriel Yariv and Eyal Barad in the total of $449,697 under Accounts payable and accrued liabilities.

 

The Company had a balance outstanding at May 31st, 2023 and at May 31, 2022 of $223,645, payable to Cannabics, Inc. The advance is due on demand and bears no interest.

 

During the nine months ending May 31, 2023, the Company recorded a non-cash expense of $145,505 in share-based payment, to the company chairman, board members and advisor.

 

Note 3 – Stockholders’ Equity (Deficit)

 

Authorized Shares

 

The Company is authorized to issue up to 900,000,000 shares of common stock, par value $0.0001 per share. There is also 100,000,000 shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

 

For the period ending at May 31, 2023, the company issued 14,795,073 shares as a result of a convertible of a loan at the total of $470,131.

 

Note 4 – Commitments and Contingencies

 

We currently rent our laboratory located in Rehovot, Israel, for a monthly fee of $6,500. Our existing lease agreement will expire at the end of February 2024. Although we have the option to renew for two additional years, it is more unlikely than likely that we will exercise the two-year option

 

As security for its obligation under credit cards, the Company’s subsidiary provided a bank guarantee in the amount of shekels $5,700.

 

Note 5 – Subsequent Events

 

On June 1, 2023, the company issued 1,000, 000 shares as a result of a convertible of a loan at the total of $11,491.

 

 

 

 

 

 11 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Company Overview

 

We are a pre-clinical-stage, platform technology biopharmaceutical company which has developed proprietary innovative medicines in areas of significant unmet medical needs in oncology, with a current focus on colorectal cancer ("CRC"). Our drug candidate under development for colon cancer is RCC-33, a first-in-class therapy being developed primarily in two settings: one to reduce tumor cell activity in colon cancer patients as a standalone in neoadjuvant treatment or "window of opportunity" at the time after colonoscopy, prior to cancer staging; and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company hopes to start first in human Phase I/II clinical trials in 2024. Neoadjuvant treatment is the administration of a therapy before the surgical treatment to improve patient outcome, and our business strategy is to advance our programs through clinical studies including with partners, and to opportunistically add programs in areas of high unmet medical needs through acquisition, collaboration, or internal development.

 

Results of Operations

 

For the Three Months Ended May 31st, 2023 and 2022

 

Revenues

 

For the three months ended May 31, 2023, our total income $310,165 compared to non for the three months ended May 31, 2022

The company revenues are consisting of laboratory services.

 

Operating Expenses

 

For the three months ended May 31, 2023, our total operating expenses were $483,247 compared to $635,006 for the three months ended May 31, 2022, resulting in a decrease of $151,759. The decrease is attributable to a decrease of $165,813 in general administration, and sales and marketing expenses and a decrease of $75,215 in research and development expenses.

 

We realized financial gain of $18,392 for the three months ended May 31st, 2023, compared to incurring financial loss of $46,646 for the three months ended May 31, 2022.

 

As a result, the net loss was $154,690 for the three months ended May 31st, 2023, compared to a net loss of $681,652 for the three months ended May 31, 2022.

 

Net Loss

 

Net loss was $154,690 compared to net loss $681,652 for the three months ended May 31st, 2023, for the reasons noted supra.

 

For the nine Months Ended May 31st, 2023 and 2022

 

Revenues

 

For the nine months ended May 31, 2023, our total income $310,165 compared to non for the nine months ended May 31, 2022.

 

The company revenues are consisting of laboratory services.

 

 

 

 12 

 

 

Operating Expenses

 

For the nine months ended May 31st, 2023, our total operating expenses were $1,080,046 compared to $2,475,617 for the nine months ended May 31, 2022, resulting in a decrease of $1,395,571. The decrease is attributable to a decrease of $741,219 in general administration, and sales and marketing expenses mostly due to share based payment of $490,082 and Professional services of $284,975and a decrease of $681,352 in research and development expenses.

 

We realized financial income of $28,499 for the nine months ended May 31, 2023, compared to financial loss of $767,926 for the nine months ended May 31, 2022. The decrease in financial expense was mainly attributable to a convertible loan valuation expense of $9,033 for the nine month ended May 31,2023 comparing to $718,392 for the nine months ended May 31, 2022.

 

We realized capital loss due to a realization of the Company’s shares held in Sativus Inc of $2,395,298 for the nine months ended May 31,2023 comparing to none for the nine months ended May 31, 2022.

 

As a result, the net loss was $3,136,680 for the nine months ended May 31st, 2023, compared to a net loss of $3,243,543 for the nine months ended May 31, 2022.

 

Net loss

 

Net loss was $3,136,680 compared to net income of $3,243,543 for the nine months ended May 31st, 2023 and May 31, 2022, for the reasons explained supra.

 

Liquidity and Capital Resources

 

Overview

 

As of May 31st, 2023, we had $44,151 in cash compared to $117,515 on August 31, 2022. We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. We estimate that these expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research and development expenses, and fees payable to outside medical centers for clinical studies.

 

Liquidity and Capital Resources during the nine Months Ended May 31st, 2023 compared to the nine Months Ended May 31, 2022

 

We used cash in operations of $133,038 for the nine months ended May 31st, 2023 compared to cash used in operations of $1,529,683 for the nine months ended May 31, 2022. The negative cash flow from operating activities for the nine months ended May 31st, 2023 is primarily attributable to the Company's net loss from operations of $3,163,680, offset by depreciation of $123,569, an increase in accounts payables and accrued liabilities of $554,110, an increase of $223,873 in account receivables and prepaid expenses, convertible loan valuation of $9,033, and share based payment in a total of $145,505.

 

We had cash flow from investing activities of $24,702 during the nine months ended May 31st, 2023, compared to cash flow used investing activities of $513 for the nine months ended May 31, 2022. The cash flow from investing activities is due to the Company’s Realization of Sativus Inc shares of $24,702.

 

We had cash flow from financing activities of $34,972 convertible loan during the nine months ended May 31st, 2023, compared to $240,000 convertible loan for the nine months ended May 31, 2022.

 

We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.

 

 

 

 13 

 

 

Going Concern

 

Due to the uncertainty of our ability to meet our current operating and capital expenses, our independent auditors included an explanatory paragraph in their report on the audited financial statements for the year ended August 31, 2022 regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

 

Our unaudited financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our unaudited financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.

 

There is no assurance that our operations will be profitable. Our continued existence and plans for future growth depend on our ability to obtain the additional capital necessary to operate either through the generation of revenue or the issuance of additional debt or equity.

 

Off-Balance Sheet Arrangements

 

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

 

See Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2, “Summary of Significant Accounting Policies” in our audited consolidated financial statements for the year ended August 31, 2022, included in our Annual Report on Form 10-K as filed on November 30th, 2022, for a discussion of our critical accounting policies and estimates.

 

 

 

 

 

 14 

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

The disclosure required under this item is not required to be reported by smaller reporting companies; as such term is defined by Item 503(e) of Regulation S-K.

 

Item 4. Controls and Procedures.

 

  (a) Evaluation of Disclosure Controls and Procedures

 

The Company maintains a set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In accordance with Rule 13a-15(b) of the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including its Chief Executive Officer, Chief Financial Officer and the full Audit Committee, of the effectiveness of its disclosure controls and procedures. The Audit Committee assessed, reviewed and determined that the Company’s disclosure controls and procedures were effective as to this quarterly filing. Based on that evaluation, The Board accepted and ratified the findings of the Audit Committee that the Company’s disclosure controls and procedures, as of May 31st, 2023, the end of the period covered by this Quarterly Report on Form 10-Q, were effective to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer, Chief Financial Officer, and Audit Committee as appropriate to allow timely decisions regarding required disclosure.

 

  (b) Changes in Internal Control over Financial Reporting

 

Since our annual report, the Company has maintained an Audit Committee to better review our internal financial reporting. There were no other changes in our internal control over financial reporting during the period ending May 31, 2023, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

  (c) Limitations on the Effectiveness of Internal Controls

 

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

 

 

 

 

 

 15 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

None.

 

Item 1A. Risk Factors

 

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 2. Recent Sale of Unregistered Securities

 

None.

 

Item 6. Exhibits

 

Exhibit 31.1* Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).
   
Exhibit 31.2* Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).
   
Exhibit 32.1** Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
Exhibit 32.2** Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS*** XBRL Instance Document
   
101.SCH*** XBRL Taxonomy Extension Schema Document
   
101.CAL*** XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF*** XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB*** XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE*** XBRL Taxonomy Extension Presentation Linkbase Document

______________________________

* Filed herewith.
   
** Furnished herewith.
   
*** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

 

 

 16 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  CNBX Pharmaceuticals Inc.
     
Date: July 14, 2023 By: /s/ Eyal Barad
    Eyal Barad
  Title:

Chief Executive Officer

(Principal Executive Officer)

     
     
Date: July 14, 2023 By: /s/ Uri Ben Or
    Uri Ben Or
  Title:

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 17 

 

 EX-31.1 2 cnbx_ex3101.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Eyal Barad, certify that:

 

1. I have reviewed this Form 10-Q of CNBX PHARMACEUTICALS INC.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
     
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
     
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: July 14, 2023 By: /s/ Eyal Barad  
    Eyal Barad  
   

Director, Chief Executive Officer

CNBX PHARMACEUTICALS INC.

  

 

 EX-31.2 3 cnbx_ex3102.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Uri Ben Or, certify that:

 

1. I have reviewed this Form 10-Q of CNBX PHARMACEUTICALS INC.;
     
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
     
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
     
  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: July 14, 2023 By: /s/ Uri Ben Or  
    Uri Ben Or  
   

Chief Financial Officer

CNBX PHARMACEUTICALS INC.

  

 

 

 EX-32.1 4 cnbx_ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

 

 

In connection with this Quarterly Report of CNBX PHARMACEUTICALS INC. (the “Company”) on Form 10-Q for the quarter ending May 31st, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Eyal Barad, Director and Chief Executive Officer (Principal Executive Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. Such Quarterly Report on Form 10-Q for the quarter ending May 31st, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in such Quarterly Report on Form 10-Q for the quarter ending May 31st, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

       
Date: July 14, 2023 By: /s/ Eyal Barad  
    Eyal Barad  
   

Director, Chief Executive Officer

CNBX PHARMACEUTICALS INC.

  

 

 EX-32.2 5 cnbx_ex3202.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report of CNBX PHARMACEUTICALS INC. (the “Company”) on Form 10-Q for the quarter ending May 31st, 2023, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Uri Ben Or, Chief Financial Officer (Principal Financial Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 

1. Such Quarterly Report on Form 10-Q for the quarter ending May 31st, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in such Quarterly Report on Form 10-Q for the quarter ending May 31st, 2023, fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

       
Date: July 14, 2023 By: /s/ Uri Ben Or  
    Uri Ben Or  
   

Chief Financial Officer

CNBX PHARMACEUTICALS INC.

  

 

 EX-101.SCH 6 cnbx-20230531.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Business, Presentation and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Nature of Business, Presentation and Going Concern (Policies) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stockholders’ Equity (Deficit) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cnbx-20230531_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cnbx-20230531_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cnbx-20230531_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Warrants [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Retained Earnings [Member] Counterparty Name [Axis] Two Directors [Member] Related Party, Type [Axis] Yariv And Barad [Member] Cannabics [Member] Nonmonetary Transaction Type [Axis] Share Based Payment [Member] Chairman Board Members And Advisor [Member] Subsidiary [Member] Currency [Axis] Israel, New Shekels Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Prepaid expenses and other receivables Total current assets Available for sale Investment Equipment, net Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued liabilities Convertible loan Due to a related party Total current liabilities Stockholders' equity (deficit): Preferred stock, $0.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding. Common stock, $0.0001 par value, 900,000,000 shares authorized, 16,033,732 shares issued and outstanding at May 31, 2023 and 1,257,927 shares issued and outstanding at August 31, 2022. Additional paid-in capital Issuance of warrants Other comprehensive loss Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Revenues Operating expenses: Research and development expense General and administrative expenses Total operating expenses Loss from operations Other income Capital Loss Financial Income (Loss) Net loss Profit (loss) from available for sale assets Total comprehensive (income) loss Net loss per share - basic Net loss per share - diluted Weighted average number of shares outstanding - Basic Weighted average number of shares outstanding - Diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Exercise of CLA to shares Beginning balance, shares Share based payment Realization of available for sale asset Net Loss Other comprehensive gain Ending balance, value Beginning balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments required to reconcile net loss to net cash used in operating activities: Depreciation Interest on loans Capital Gain Due to related party Royalties receivables valuation Stock issued for services Profit from held for trading investments Convertible loan valuation Share based payment Changes in operating assets and liabilities: Accounts Receivable and pre paid expenses Accounts payable and accrued liabilities Net cash used in operating activities Cash flows from investing activities: Proceeds from sale of available for sale investments Acquisition of equipment Net cash gain in investing activities Cash flows from financing activities: Convertible loan Net cash provided by financing activities Effect of exchange rate fluctuations on cash Net decrease in cash Cash and cash equivalents at beginning of the Period Cash and cash equivalents at end of the Period Significant non-cash transactions: Exercise of a Convertible loan to shares of common stock. Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business, Presentation and Going Concern Related Party Transactions [Abstract] Related Party Transactions Equity [Abstract] Stockholders’ Equity (Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Organization Basis of Presentation Principles of Consolidation Going Concern Research and Development Costs Reclassifications Net Income (Loss) Attributable to Parent Retained Earnings (Accumulated Deficit) Research and Development Expense Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Accrued Salaries Accounts Payable and Accrued Liabilities, Current [custom:DueToRelatedPartiesCurrent1-0] Other Noncash Expense Debt Conversion, Converted Instrument, Shares Issued Debt Conversion, Converted Instrument, Amount Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Monthly operating lease expense Other Commitment Organization Policy [Policy Text Block] Assets, Current Assets Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding CapitalLoss1 Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Machinery and Equipment Proceeds from Convertible Debt Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents EX-101.PRE 10 cnbx-20230531_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - shares
 9 Months Ended
May 31, 2023
Jul. 14, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date May 31, 2023  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --08-31  
Entity File Number 000-52403  
Entity Registrant Name CNBX PHARMACEUTICALS INC.  
Entity Central Index Key 0001343009  
Entity Tax Identification Number 46-5644005  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One #3 Bethesda Metro Center  
Entity Address, Address Line Two Suite 700  
Entity Address, City or Town Bethesda  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 20814  
City Area Code (877)  
Local Phone Number 424-2429  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   17,033,732
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets (Unaudited) - USD ($)
May 31, 2023
Aug. 31, 2022
Current assets:    
Cash and cash equivalents $ 44,151 $ 117,515
Prepaid expenses and other receivables 304,645 80,772
Total current assets 348,796 198,287
Available for sale Investment 0 176,087
Equipment, net 313,223 436,792
Total assets 662,019 811,166
Current liabilities:    
Accounts payable and accrued liabilities 1,015,240 461,128
Convertible loan 1,332,577 1,758,702
Due to a related party 223,645 223,645
Total current liabilities 2,571,462 2,443,475
Stockholders' equity (deficit):    
Preferred stock, $0.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding. 0 0
Common stock, $0.0001 par value, 900,000,000 shares authorized, 16,033,732 shares issued and outstanding at May 31, 2023 and 1,257,927 shares issued and outstanding at August 31, 2022. 1,603 124
Additional paid-in capital 18,646,026 18,031,869
Issuance of warrants 3,459,510 3,459,510
Other comprehensive loss (330,933) (2,574,846)
Accumulated deficit (23,685,648) (20,548,968)
Total stockholders' equity (1,909,442) (1,632,311)
Total liabilities and stockholders' equity $ 662,019 $ 811,166
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
May 31, 2023
Aug. 31, 2022
Statement of Financial Position [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Preferred Stock, Shares Authorized 100,000,000 100,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 900,000,000 900,000,000
Common Stock, Shares, Issued 16,033,732 1,257,927
Common Stock, Shares, Outstanding 16,033,732 1,257,927
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
May 31, 2023
May 31, 2022
May 31, 2023
May 31, 2022
Income Statement [Abstract]        
Revenues $ 310,165 $ 0 $ 310,165 $ 0
Operating expenses:        
Research and development expense 263,115 249,061 338,330 1,019,682
General and administrative expenses 220,132 385,945 741,716 1,455,935
Total operating expenses 483,247 635,006 1,080,046 2,475,617
Loss from operations (173,082) (635,006) (769,881) (2,475,617)
Other income        
Capital Loss 0 0 (2,395,298) 0
Financial Income (Loss) 18,392 (46,646) 28,499 (767,926)
Net loss (154,690) (681,652) (3,136,680) (3,243,543)
Profit (loss) from available for sale assets 0 42,261 (59,870) (605,740)
Total comprehensive (income) loss $ (154,690) $ (639,392) $ (3,196,550) $ (3,849,283)
Net loss per share - basic $ (0.02) $ (0.05) $ (0.78) $ (2.65)
Net loss per share - diluted $ (0.02) $ (0.05) $ (0.78) $ (2.65)
Weighted average number of shares outstanding - Basic 9,265,865 1,238,826 4,030,048 1,221,478
Weighted average number of shares outstanding - Diluted 9,265,865 1,238,826 4,030,048 1,221,478
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Warrants [Member]
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Aug. 31, 2021 $ 122 $ 17,077,715 $ 3,459,510 $ (1,905,715) $ (16,825,718) $ 1,805,914
Beginning balance, shares at Aug. 31, 2021 1,218,799          
Exercise of CLA to shares $ 2 225,287 225,289
Beginning balance, shares 20,027          
Share based payment 635,587 635,587
Net Loss (3,243,543) (3,243,543)
Other comprehensive gain (605,740) (605,740)
Ending balance, value at May. 31, 2022 $ 124 17,938,589 3,459,510 (2,511,455) (20,069,261) (1,182,493)
Beginning balance, shares at May. 31, 2022 1,238,826          
Beginning balance, value at Feb. 28, 2022 $ 124 17,833,663 3,459,510 (2,553,716) (19,387,609) (648,028)
Beginning balance, shares at Feb. 28, 2022 1,238,826          
Share based payment 104,926 104,926
Net Loss (681,652) (681,652)
Other comprehensive gain 42,261 42,261
Ending balance, value at May. 31, 2022 $ 124 17,938,589 3,459,510 (2,511,455) (20,069,261) (1,182,493)
Beginning balance, shares at May. 31, 2022 1,238,826          
Beginning balance, value at Aug. 31, 2022 $ 124 18,031,869 3,459,510 (2,574,846) (20,548,968) (1,632,311)
Beginning balance, shares at Aug. 31, 2022 1,238,659          
Exercise of CLA to shares $ 1,479 468,652 470,131
Beginning balance, shares 14,795,073          
Share based payment 145,505 145,505
Realization of available for sale asset 2,243,913 2,243,913
Net Loss (3,136,680) (3,136,680)
Ending balance, value at May. 31, 2023 $ 1,603 18,646,026 3,459,510 (330,933) (23,685,648) (1,909,442)
Beginning balance, shares at May. 31, 2023 16,033,732          
Beginning balance, value at Feb. 28, 2023 $ 222 18,390,628 3,459,510 (330,933) (23,530,958) (2,011,531)
Beginning balance, shares at Feb. 28, 2023 2,190,138          
Exercise of CLA to shares $ 1,381 220,423 221,804
Beginning balance, shares 13,843,594          
Share based payment 34,975 34,975
Net Loss (154,690) (154,690)
Ending balance, value at May. 31, 2023 $ 1,603 $ 18,646,026 $ 3,459,510 $ (330,933) $ (23,685,648) $ (1,909,442)
Beginning balance, shares at May. 31, 2023 16,033,732          
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
May 31, 2023
May 31, 2022
Cash flows from operating activities:    
Net Loss $ (3,136,680) $ (3,243,543)
Adjustments required to reconcile net loss to net cash used in operating activities:    
Depreciation 123,569 151,239
Interest on loans 0 0
Capital Gain 2,395,298 0
Due to related party 0 0
Royalties receivables valuation 0 0
Stock issued for services 0 0
Profit from held for trading investments 0 0
Convertible loan valuation 9,033 718,392
Share based payment 145,505 635,587
Changes in operating assets and liabilities:    
Accounts Receivable and pre paid expenses (223,873) 66,560
Accounts payable and accrued liabilities 554,110 142,083
Net cash used in operating activities (133,038) (1,529,682)
Cash flows from investing activities:    
Proceeds from sale of available for sale investments 24,702 0
Acquisition of equipment 0 (513)
Net cash gain in investing activities 24,702 (513)
Cash flows from financing activities:    
Convertible loan 34,972 240,000
Net cash provided by financing activities 34,972 240,000
Effect of exchange rate fluctuations on cash 0 0
Net decrease in cash (73,364) (1,290,195)
Cash and cash equivalents at beginning of the Period 117,515 1,386,472
Cash and cash equivalents at end of the Period 44,151 96,277
Significant non-cash transactions:    
Exercise of a Convertible loan to shares of common stock. $ 470,131 $ 225,287
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of Business, Presentation and Going Concern
 9 Months Ended
May 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business, Presentation and Going Concern

Note 1 – Nature of Business, Presentation and Going Concern

 

Organization

 

CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.

 

On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.

 

On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, CNBX Pharmaceuticals Inc. purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.

 

On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.

 

On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.

 

On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.

 

On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.

 

On August 20th, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including in-vivo experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.

  

On February 13th, 2022, the company established a Nomination and Governance Committee.

 

 

 

 

On May 10, 2022, the Company filed a certificate of change (the “Certificate”) with the Secretary of State of the State of Nevada. Pursuant to the Certificate, the Company effectuated a one-for-one hundred twenty (1:120) reverse split of the issued and outstanding shares of common stock of the Company without changing the par value of the stock.

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

These unaudited financial statements should be read in conjunction with our August 31, 2022 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 30th, 2022.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiaries GRIN Ultra and Digestix Bioscience Inc. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Going Concern

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $3,136,680 for the nine months ended May 31st, 2023, it has incurred cumulative losses since inception of $23,685,648. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

 

Research and Development Costs

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $338,330 and $1,019,682 for the nine months ended May 31st, 2023 and 2022, respectively.

 

Reclassifications

 

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.

 

 

 

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions
 9 Months Ended
May 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

Note 2 – Related Party Transactions

 

During the nine months ending May 31st, 2023, the Company paid $7,000 in salaries, including socials benefits, to two directors, compared to $264,061 for the nine months ending May 31, 2022.

 

During the nine months ending May 31st, 2023 the Company accrued $334,658 in salaries, including socials benefits, to two directors compared to $115,039 for the nine months ending May 31, 2022.

 

As of May 31, 2023, the Company had a balance outstanding payable to two directors: Gabriel Yariv and Eyal Barad in the total of $449,697 under Accounts payable and accrued liabilities.

 

The Company had a balance outstanding at May 31st, 2023 and at May 31, 2022 of $223,645, payable to Cannabics, Inc. The advance is due on demand and bears no interest.

 

During the nine months ending May 31, 2023, the Company recorded a non-cash expense of $145,505 in share-based payment, to the company chairman, board members and advisor.

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity (Deficit)
 9 Months Ended
May 31, 2023
Equity [Abstract]  
Stockholders’ Equity (Deficit)

Note 3 – Stockholders’ Equity (Deficit)

 

Authorized Shares

 

The Company is authorized to issue up to 900,000,000 shares of common stock, par value $0.0001 per share. There is also 100,000,000 shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

 

For the period ending at May 31, 2023, the company issued 14,795,073 shares as a result of a convertible of a loan at the total of $470,131.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
 9 Months Ended
May 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 4 – Commitments and Contingencies

 

We currently rent our laboratory located in Rehovot, Israel, for a monthly fee of $6,500. Our existing lease agreement will expire at the end of February 2024. Although we have the option to renew for two additional years, it is more unlikely than likely that we will exercise the two-year option

 

As security for its obligation under credit cards, the Company’s subsidiary provided a bank guarantee in the amount of shekels $5,700.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events
 9 Months Ended
May 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 5 – Subsequent Events

 

On June 1, 2023, the company issued 1,000, 000 shares as a result of a convertible of a loan at the total of $11,491.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of Business, Presentation and Going Concern (Policies)
 9 Months Ended
May 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization

Organization

 

CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.

 

On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.

 

On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, CNBX Pharmaceuticals Inc. purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.

 

On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.

 

On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.

 

On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.

 

On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.

 

On August 20th, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including in-vivo experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.

  

On February 13th, 2022, the company established a Nomination and Governance Committee.

 

 

 

 

On May 10, 2022, the Company filed a certificate of change (the “Certificate”) with the Secretary of State of the State of Nevada. Pursuant to the Certificate, the Company effectuated a one-for-one hundred twenty (1:120) reverse split of the issued and outstanding shares of common stock of the Company without changing the par value of the stock.

 
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

 

These unaudited financial statements should be read in conjunction with our August 31, 2022 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 30th, 2022.

 
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its subsidiaries GRIN Ultra and Digestix Bioscience Inc. All significant inter-company balances and transactions have been eliminated in consolidation.

 
Going Concern

Going Concern

 

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $3,136,680 for the nine months ended May 31st, 2023, it has incurred cumulative losses since inception of $23,685,648. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

 
Research and Development Costs

Research and Development Costs

 

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $338,330 and $1,019,682 for the nine months ended May 31st, 2023 and 2022, respectively.

 
Reclassifications

Reclassifications

 

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.

 

 

 

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of Business, Presentation and Going Concern (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
May 31, 2023
May 31, 2022
May 31, 2023
May 31, 2022
Aug. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Net Income (Loss) Attributable to Parent $ 154,690 $ 681,652 $ 3,136,680 $ 3,243,543  
Retained Earnings (Accumulated Deficit) 23,685,648   23,685,648   $ 20,548,968
Research and Development Expense $ 263,115 $ 249,061 $ 338,330 $ 1,019,682  
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions (Details Narrative) - USD ($)
 9 Months Ended
May 31, 2023
May 31, 2022
Aug. 31, 2022
Related Party Transaction [Line Items]      
Accounts Payable and Accrued Liabilities, Current $ 1,015,240   $ 461,128
Yariv And Barad [Member]      
Related Party Transaction [Line Items]      
Accounts Payable and Accrued Liabilities, Current 449,697    
Cannabics [Member]      
Related Party Transaction [Line Items]      
[custom:DueToRelatedPartiesCurrent1-0] 223,645 $ 223,645  
Two Directors [Member]      
Related Party Transaction [Line Items]      
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold 7,000 264,061  
Accrued Salaries 334,658 $ 115,039  
Chairman Board Members And Advisor [Member] | Share Based Payment [Member]      
Related Party Transaction [Line Items]      
Other Noncash Expense $ 145,505    
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)
 9 Months Ended
May 31, 2023
Aug. 31, 2022
Equity [Abstract]    
Common Stock, Shares Authorized 900,000,000 900,000,000
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Preferred Stock, Shares Authorized 100,000,000 100,000,000
Debt Conversion, Converted Instrument, Shares Issued 14,795,073  
Debt Conversion, Converted Instrument, Amount $ 470,131  
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Details Narrative)
 9 Months Ended
May 31, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Monthly operating lease expense $ 6,500
Subsidiary [Member] | Israel, New Shekels  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Other Commitment $ 5,700
XML 27 cnbx_i10q-053123_htm.xml IDEA: XBRL DOCUMENT 0001343009 2022-09-01 2023-05-31 0001343009 2023-07-14 0001343009 2023-05-31 0001343009 2022-08-31 0001343009 2023-03-01 2023-05-31 0001343009 2022-03-01 2022-05-31 0001343009 2021-09-01 2022-05-31 0001343009 us-gaap:CommonStockMember 2022-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001343009 CNBX:WarrantsMember 2022-08-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-08-31 0001343009 us-gaap:RetainedEarningsMember 2022-08-31 0001343009 us-gaap:CommonStockMember 2023-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2023-02-28 0001343009 CNBX:WarrantsMember 2023-02-28 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-02-28 0001343009 us-gaap:RetainedEarningsMember 2023-02-28 0001343009 2023-02-28 0001343009 us-gaap:CommonStockMember 2021-08-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001343009 CNBX:WarrantsMember 2021-08-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-08-31 0001343009 us-gaap:RetainedEarningsMember 2021-08-31 0001343009 2021-08-31 0001343009 us-gaap:CommonStockMember 2022-02-28 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001343009 CNBX:WarrantsMember 2022-02-28 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-02-28 0001343009 us-gaap:RetainedEarningsMember 2022-02-28 0001343009 2022-02-28 0001343009 us-gaap:CommonStockMember 2022-09-01 2023-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-09-01 2023-05-31 0001343009 CNBX:WarrantsMember 2022-09-01 2023-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-09-01 2023-05-31 0001343009 us-gaap:RetainedEarningsMember 2022-09-01 2023-05-31 0001343009 us-gaap:CommonStockMember 2023-03-01 2023-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2023-03-01 2023-05-31 0001343009 CNBX:WarrantsMember 2023-03-01 2023-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-01 2023-05-31 0001343009 us-gaap:RetainedEarningsMember 2023-03-01 2023-05-31 0001343009 us-gaap:CommonStockMember 2021-09-01 2022-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2022-05-31 0001343009 CNBX:WarrantsMember 2021-09-01 2022-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-09-01 2022-05-31 0001343009 us-gaap:RetainedEarningsMember 2021-09-01 2022-05-31 0001343009 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001343009 CNBX:WarrantsMember 2022-03-01 2022-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-01 2022-05-31 0001343009 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001343009 us-gaap:CommonStockMember 2023-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001343009 CNBX:WarrantsMember 2023-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-05-31 0001343009 us-gaap:RetainedEarningsMember 2023-05-31 0001343009 us-gaap:CommonStockMember 2022-05-31 0001343009 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001343009 CNBX:WarrantsMember 2022-05-31 0001343009 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-05-31 0001343009 us-gaap:RetainedEarningsMember 2022-05-31 0001343009 2022-05-31 0001343009 CNBX:TwoDirectorsMember 2022-09-01 2023-05-31 0001343009 CNBX:TwoDirectorsMember 2021-09-01 2022-05-31 0001343009 CNBX:TwoDirectorsMember 2023-05-31 0001343009 CNBX:TwoDirectorsMember 2022-05-31 0001343009 CNBX:YarivAndBaradMember 2023-05-31 0001343009 CNBX:CannabicsMember 2023-05-31 0001343009 CNBX:CannabicsMember 2022-05-31 0001343009 CNBX:ChairmanBoardMembersAndAdvisorMember CNBX:ShareBasedPaymentMember 2022-09-01 2023-05-31 0001343009 CNBX:SubsidiaryMember currency:ILS 2023-05-31 iso4217:USD shares iso4217:USD shares pure 0001343009 false --08-31 2023 Q3 10-Q true 2023-05-31 false 000-52403 CNBX PHARMACEUTICALS INC. NV 46-5644005 #3 Bethesda Metro Center Suite 700 Bethesda MD 20814 (877) 424-2429 Yes Yes Non-accelerated Filer true false false 17033732 44151 117515 304645 80772 348796 198287 0 176087 313223 436792 662019 811166 1015240 461128 1332577 1758702 223645 223645 2571462 2443475 0.0001 0.0001 100000000 100000000 0 0 0 0 0 0 0.0001 0.0001 900000000 900000000 16033732 16033732 1257927 1257927 1603 124 18646026 18031869 3459510 3459510 -330933 -2574846 -23685648 -20548968 -1909442 -1632311 662019 811166 310165 0 310165 0 263115 249061 338330 1019682 220132 385945 741716 1455935 483247 635006 1080046 2475617 -173082 -635006 -769881 -2475617 0 0 -2395298 0 18392 -46646 28499 -767926 -154690 -681652 -3136680 -3243543 0 42261 -59870 -605740 -154690 -639392 -3196550 -3849283 -0.02 -0.05 -0.78 -2.65 -0.02 -0.05 -0.78 -2.65 9265865 1238826 4030048 1221478 9265865 1238826 4030048 1221478 1238659 124 18031869 3459510 -2574846 -20548968 -1632311 14795073 1479 468652 470131 145505 145505 2243913 2243913 -3136680 -3136680 16033732 1603 18646026 3459510 -330933 -23685648 -1909442 2190138 222 18390628 3459510 -330933 -23530958 -2011531 13843594 1381 220423 221804 34975 34975 -154690 -154690 16033732 1603 18646026 3459510 -330933 -23685648 -1909442 1218799 122 17077715 3459510 -1905715 -16825718 1805914 20027 2 225287 225289 635587 635587 -605740 -605740 -3243543 -3243543 1238826 124 17938589 3459510 -2511455 -20069261 -1182493 1238826 124 17833663 3459510 -2553716 -19387609 -648028 104926 104926 42261 42261 -681652 -681652 1238826 124 17938589 3459510 -2511455 -20069261 -1182493 -3136680 -3243543 123569 151239 0 0 -2395298 -0 0 0 0 0 0 0 0 0 9033 718392 145505 635587 223873 -66560 554110 142083 -133038 -1529682 24702 0 -0 513 24702 -513 34972 240000 34972 240000 0 0 -73364 -1290195 117515 1386472 44151 96277 470131 225287 <p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z9Pk2xkM9Wd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 1 – <span id="xdx_82A_zyKu1JDTxY2l">Nature of Business, Presentation and Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84A_ecustom--OrganizationPolicyPolicyTextBlock_zewcKCDF1PYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_z3n82jrOXlXe">Organization</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, CNBX Pharmaceuticals Inc. purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2014, FINRA granted final approval of Change of Name &amp; Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 20<sup>th</sup>, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including <i>in-vivo</i> experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 13<sup>th</sup>, 2022, the company established a Nomination and Governance Committee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 10, 2022, the Company filed a certificate of change (the “Certificate”) with the Secretary of State of the State of Nevada. Pursuant to the Certificate, the Company effectuated a one-for-one hundred twenty (1:120) reverse split of the issued and outstanding shares of common stock of the Company without changing the par value of the stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2uKVYhRsGtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zcgfiZ20Qpr8">Basis of Presentation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited financial statements should be read in conjunction with our August 31, 2022 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 30<sup>th</sup>, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zAuOf7juvoZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zwVKdh443HC8">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its subsidiaries GRIN Ultra and Digestix Bioscience Inc. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p id="xdx_843_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zcJW3DG0U5g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zCLI1sYYMp1e">Going Concern</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20220901__20230531_zT4ptnHMi2Sj">3,136,680</span> for the nine months ended May 31st, 2023, it has incurred cumulative losses since inception of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230531_zWcyIrwkH4G3">23,685,648</span>. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqnFQtEEQTRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zSLwvZ2UT4R2">Research and Development Costs</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220901__20230531_zYFmWsLmhDS4">338,330</span> and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210901__20220531_z4W3qIR1ndq8">1,019,682</span> for the nine months ended May 31st, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zUUqa55GzM8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zF3BNP3gbMxa">Reclassifications</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_ecustom--OrganizationPolicyPolicyTextBlock_zewcKCDF1PYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_z3n82jrOXlXe">Organization</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, CNBX Pharmaceuticals Inc. purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2014, FINRA granted final approval of Change of Name &amp; Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 20<sup>th</sup>, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including <i>in-vivo</i> experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 13<sup>th</sup>, 2022, the company established a Nomination and Governance Committee.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 10, 2022, the Company filed a certificate of change (the “Certificate”) with the Secretary of State of the State of Nevada. Pursuant to the Certificate, the Company effectuated a one-for-one hundred twenty (1:120) reverse split of the issued and outstanding shares of common stock of the Company without changing the par value of the stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2uKVYhRsGtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zcgfiZ20Qpr8">Basis of Presentation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These unaudited financial statements should be read in conjunction with our August 31, 2022 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November 30<sup>th</sup>, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zAuOf7juvoZ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zwVKdh443HC8">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its subsidiaries GRIN Ultra and Digestix Bioscience Inc. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p id="xdx_843_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zcJW3DG0U5g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zCLI1sYYMp1e">Going Concern</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20220901__20230531_zT4ptnHMi2Sj">3,136,680</span> for the nine months ended May 31st, 2023, it has incurred cumulative losses since inception of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230531_zWcyIrwkH4G3">23,685,648</span>. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> -3136680 -23685648 <p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zqnFQtEEQTRg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zSLwvZ2UT4R2">Research and Development Costs</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. Research and development costs charged to expense were $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220901__20230531_zYFmWsLmhDS4">338,330</span> and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20210901__20220531_z4W3qIR1ndq8">1,019,682</span> for the nine months ended May 31st, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 338330 1019682 <p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zUUqa55GzM8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zF3BNP3gbMxa">Reclassifications</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zoKTE4kHlTk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 – <span id="xdx_82C_znC05goNDCx7">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ending May 31st, 2023, the Company paid $<span id="xdx_904_eus-gaap--SalariesAndWages_c20220901__20230531__srt--CounterpartyNameAxis__custom--TwoDirectorsMember_zR99a4EhMQ74">7,000</span> in salaries, including socials benefits, to two directors, compared to $<span id="xdx_90F_eus-gaap--SalariesAndWages_c20210901__20220531__srt--CounterpartyNameAxis__custom--TwoDirectorsMember_zDfam6PC2iz9">264,061</span> for the nine months ending May 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ending May 31st, 2023 the Company accrued $<span id="xdx_906_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20230531__srt--CounterpartyNameAxis__custom--TwoDirectorsMember_z9Jh0f5fjoY5">334,658</span> in salaries, including socials benefits, to two directors compared to $<span id="xdx_904_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20220531__srt--CounterpartyNameAxis__custom--TwoDirectorsMember_zcRyPwZCnmia">115,039</span> for the nine months ending May 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of May 31, 2023, the Company had a balance outstanding payable to two directors: Gabriel Yariv and Eyal Barad in the total of $<span id="xdx_90D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--YarivAndBaradMember_ztiSV4SZCUVb">449,697</span> under Accounts payable and accrued liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company had a balance outstanding at May 31st, 2023 and at May 31, 2022 of $<span id="xdx_90C_ecustom--DueToRelatedPartiesCurrent1_iI_c20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CannabicsMember_zMpnumg7WEw"><span id="xdx_90D_ecustom--DueToRelatedPartiesCurrent1_iI_c20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CannabicsMember_zOqLhk5jU6Ea">223,645</span></span>, payable to Cannabics, Inc. The advance is due on demand and bears no interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ending May 31, 2023, the Company recorded a non-cash expense of $<span id="xdx_90B_eus-gaap--OtherNoncashExpense_c20220901__20230531__us-gaap--NonmonetaryTransactionTypeAxis__custom--ShareBasedPaymentMember__srt--CounterpartyNameAxis__custom--ChairmanBoardMembersAndAdvisorMember_zttQ1eTPe3ve">145,505</span> in share-based payment, to the company chairman, board members and advisor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p> 7000 264061 334658 115039 449697 223645 223645 145505 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zEfppj5smQOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><b>Note 3 – <span id="xdx_821_z1XlKVxRgf14">Stockholders’ Equity (Deficit)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><b><i>Authorized Shares</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company is authorized to issue up to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230531_zBD5MrcWPrjf">900,000,000</span> shares of common stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230531_zIsvuB7ukb31">0.0001</span> per share. There is also <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20230531_z1bZrK6OnPz3">100,000,000</span> shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">For the period ending at May 31, 2023, the company issued <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220901__20230531_zYrCPqSqXua8">14,795,073</span> shares as a result of a convertible of a loan at the total of $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220901__20230531_z5jvLzL5FBi5">470,131</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></p> 900000000 0.0001 100000000 14795073 470131 <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zmM0jxWmsJv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><b>Note 4 – <span id="xdx_828_zqz29LBJGHq1">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">We currently rent our laboratory located in Rehovot, Israel, for a monthly fee of $<span id="xdx_905_ecustom--MonthlyOperatingLeaseExpense_c20220901__20230531_zWx6WupanuT2" title="Monthly operating lease expense">6,500</span>. Our existing lease agreement will expire at the end of February 2024. Although we have the option to renew for two additional years, it is more unlikely than likely that we will exercise the two-year option</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As security for its obligation under credit cards, the Company’s subsidiary provided a bank guarantee in the amount of shekels $<span id="xdx_90C_eus-gaap--OtherCommitment_iI_c20230531__srt--CounterpartyNameAxis__custom--SubsidiaryMember__srt--CurrencyAxis__currency--ILS_zuAESlxE6O3j">5,700</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></p> 6500 5700 <p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zRYbl2PcrQ93" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><b>Note 5 – <span id="xdx_82C_z7TJfhjRbjQ9">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">On June 1, 2023, the company issued 1,000, 000 shares as a result of a convertible of a loan at the total of $11,491.</p> EXCEL 28 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^ M0"X99K>]9!:GL3X[/OSYWN?/7%WMMMANMM^Q7+15F465M,X]C MS"NH.7[1#2@:*;6IN:6N>8ZQ,< +K !L+>-1DLSBF@L575X<]EJ9V.]H"[D5 M6I'1&1X%[/'WN.NRG4"Q$5+8URSJOB5$K!9*U.(-BBQ*(H:5WG_71KQI9;E< MYT9+F45I/_ (QHK\#_/:03[P#786RS?WG$"R:);0AJ4P:+L9W?Z<&'= D_M> M:_57(2V8);?PS>BV$>K9;4->Q)X;71P.;1_$N?F7,.JR%#DL==[6H&P?1P/2 M 2JL1(,14[R&+%KH'1CG#QUP4_2^68+R(F7F@@;,3='A#8FB4$M1T.D%N^*2 MJQQ8%T)D)S^5!SD*0(Z."/DT\B#' #)P(-L-PDM+D]CUSJ'Z M8$%Y&5A?@F7RX>I.0P*3#JPP8'%ZAAQ?TY3M02P,$% @ A5/N5DJ$NYD* 0 APH !H M !X;"]?]>#6^0(/#1P3:M+-1WWX)'G#,'O9BVA-I"=/?I?^P/U&GN36#;UKKDWO? M#;Y0#;/] O!E0[WV"V-I&-]4QO6:QZ6KP>KRJFN"+$US<*\SU&'_.C,Y/RS] M9Z*IJK:D;U/^]#3P'X/A9MS5-T2LDK-V-7&AX-[-VQZF!R[&R2HY7@KECA=4 M$!J4"5 6'K04H&5XT$J 5N%!:P%:AP?E I2'!VT$:!,>M!6@;7C03H!VX4&8 MRC*F$9#>8AU!K5'F&B/H-('0NFNUG!1G8WM[W.X@@4;%-"1\TZBQ_7]_8LG*Y&WK 9.-T1:G M:1VC?Q "BQJ,PMQYL!2I7# JTF]8"*^*I5J & V'8U$X&\'&++8:Z6SR!)5: MZ9@\;V@;&V>G:0"-:?*X2VQ9TU1YKYM"18J+M2V_4;(](:?*+@?KQN. $E)Q MDM!&?@;LZU[7$$)30C)7(;XH0UEBHP7&K0;,^R5.>'15U110NF)EJ"1''T"5 M6 -$H_.=Z*"?'.F&8?>5%_,[F3X@9&UL4$L! A0#% @ A5/N5@IX8MAU!0 _QP M !@ ("!#@@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ A5/N5JW&N75V!0 [A< !@ ("! M3Q8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MA5/N5@5OKK6Z"@ &PO=V]R:W-H965T&UL4$L! A0#% @ A5/N5A/^R2>& P ^@L !D M ("!?DP 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ A5/N5F !,=N= @ ]P8 !D ("!!E@ 'AL+W=O M&PO !? M !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "%4^Y62H2[F0H! "'"@ M&@ @ %S80 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " "%4^Y6(]P]E%0! #."P $P @ &U8@ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 & 8 %\& Z9 ! end XML 29 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 30 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 70 113 1 false 12 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://cnbxpharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://cnbxpharma.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://cnbxpharma.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://cnbxpharma.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business, Presentation and Going Concern Sheet http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern Nature of Business, Presentation and Going Concern Notes 7 false false R8.htm 00000008 - Disclosure - Related Party Transactions Sheet http://cnbxpharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 8 false false R9.htm 00000009 - Disclosure - Stockholders??? Equity (Deficit) Sheet http://cnbxpharma.com/role/StockholdersEquityDeficit Stockholders??? Equity (Deficit) Notes 9 false false R10.htm 00000010 - Disclosure - Commitments and Contingencies Sheet http://cnbxpharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 10 false false R11.htm 00000011 - Disclosure - Subsequent Events Sheet http://cnbxpharma.com/role/SubsequentEvents Subsequent Events Notes 11 false false R12.htm 00000012 - Disclosure - Nature of Business, Presentation and Going Concern (Policies) Sheet http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies Nature of Business, Presentation and Going Concern (Policies) Policies 12 false false R13.htm 00000013 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative) Sheet http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative Nature of Business, Presentation and Going Concern (Details Narrative) Details http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies 13 false false R14.htm 00000014 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://cnbxpharma.com/role/RelatedPartyTransactions 14 false false R15.htm 00000015 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative) Sheet http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative Stockholders??? Equity (Deficit) (Details Narrative) Details http://cnbxpharma.com/role/StockholdersEquityDeficit 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://cnbxpharma.com/role/CommitmentsAndContingencies 16 false false All Reports Book All Reports cnbx_i10q-053123.htm cnbx-20230531.xsd cnbx-20230531_cal.xml cnbx-20230531_def.xml cnbx-20230531_lab.xml cnbx-20230531_pre.xml cnbx_ex3101.htm cnbx_ex3102.htm cnbx_ex3201.htm cnbx_ex3202.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 33 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cnbx_i10q-053123.htm": { "axisCustom": 0, "axisStandard": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 297, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 70, "dts": { "calculationLink": { "local": [ "cnbx-20230531_cal.xml" ] }, "definitionLink": { "local": [ "cnbx-20230531_def.xml" ] }, "inline": { "local": [ "cnbx_i10q-053123.htm" ] }, "labelLink": { "local": [ "cnbx-20230531_lab.xml" ] }, "presentationLink": { "local": [ "cnbx-20230531_pre.xml" ] }, "schema": { "local": [ "cnbx-20230531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 195, "entityCount": 1, "hidden": { "http://cnbxpharma.com/20230531": 4, "http://fasb.org/us-gaap/2023": 49, "http://xbrl.sec.gov/dei/2023": 5, "total": 58 }, "keyCustom": 13, "keyStandard": 100, "memberCustom": 7, "memberStandard": 5, "nsprefix": "CNBX", "nsuri": "http://cnbxpharma.com/20230531", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://cnbxpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "10", "role": "http://cnbxpharma.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "11", "role": "http://cnbxpharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "CNBX:OrganizationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Nature of Business, Presentation and Going Concern (Policies)", "menuCat": "Policies", "order": "12", "role": "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies", "shortName": "Nature of Business, Presentation and Going Concern (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "CNBX:OrganizationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2023-03-012023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Nature of Business, Presentation and Going Concern (Details Narrative)", "menuCat": "Details", "order": "13", "role": "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative", "shortName": "Nature of Business, Presentation and Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R14": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "14", "role": "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2023-05-31_custom_YarivAndBaradMember", "decimals": "0", "lang": null, "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)", "menuCat": "Details", "order": "15", "role": "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": "INF", "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "CNBX:MonthlyOperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Commitments and Contingencies (Details Narrative)", "menuCat": "Details", "order": "16", "role": "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "CNBX:MonthlyOperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://cnbxpharma.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://cnbxpharma.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2023-03-012023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2023-03-012023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2021-08-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "AsOf2021-08-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://cnbxpharma.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Nature of Business, Presentation and Going Concern", "menuCat": "Notes", "order": "7", "role": "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern", "shortName": "Nature of Business, Presentation and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "8", "role": "http://cnbxpharma.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Stockholders\u2019 Equity (Deficit)", "menuCat": "Notes", "order": "9", "role": "http://cnbxpharma.com/role/StockholdersEquityDeficit", "shortName": "Stockholders\u2019 Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cnbx_i10q-053123.htm", "contextRef": "From2022-09-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 12, "tag": { "CNBX_CannabicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cannabics [Member]" } } }, "localname": "CannabicsMember", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CNBX_CapitalLoss": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Capital Loss" } } }, "localname": "CapitalLoss", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "CNBX_CapitalLoss1": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "CapitalLoss1", "negatedLabel": "Capital Gain" } } }, "localname": "CapitalLoss1", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_ChairmanBoardMembersAndAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chairman Board Members And Advisor [Member]" } } }, "localname": "ChairmanBoardMembersAndAdvisorMember", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CNBX_ConvertibleLoanValuation": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Convertible loan valuation" } } }, "localname": "ConvertibleLoanValuation", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_DueToRelatedPartiesCurrent1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[custom:DueToRelatedPartiesCurrent1-0]" } } }, "localname": "DueToRelatedPartiesCurrent1", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CNBX_DueToRelatedParty": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Due to a related party" } } }, "localname": "DueToRelatedParty", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "CNBX_DueToRelatedPartyCashFlow": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Due to related party" } } }, "localname": "DueToRelatedPartyCashFlow", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_ExerciseOfConvertibleLoanToSharesOfCommonStock.": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Exercise of a Convertible loan to shares of common stock." } } }, "localname": "ExerciseOfConvertibleLoanToSharesOfCommonStock.", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_InterestOnLoans": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Interest on loans" } } }, "localname": "InterestOnLoans", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_MonthlyOperatingLeaseExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Monthly operating lease expense" } } }, "localname": "MonthlyOperatingLeaseExpense", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CNBX_OrganizationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization Policy [Policy Text Block]", "label": "Organization" } } }, "localname": "OrganizationPolicyPolicyTextBlock", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "CNBX_ProfitFromHeldForTradingInvestments": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Profit from held for trading investments" } } }, "localname": "ProfitFromHeldForTradingInvestments", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_RealizationOfAvailableForSaleAsset": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Realization of available for sale asset" } } }, "localname": "RealizationOfAvailableForSaleAsset", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "CNBX_RoyaltiesReceivablesValuation": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Royalties receivables valuation" } } }, "localname": "RoyaltiesReceivablesValuation", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CNBX_ShareBasedPaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Payment [Member]" } } }, "localname": "ShareBasedPaymentMember", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CNBX_SubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsidiary [Member]" } } }, "localname": "SubsidiaryMember", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CNBX_TwoDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Directors [Member]" } } }, "localname": "TwoDirectorsMember", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CNBX_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "CNBX_YarivAndBaradMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Yariv And Barad [Member]" } } }, "localname": "YarivAndBaradMember", "nsuri": "http://cnbxpharma.com/20230531", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "currency_ILS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Israel, New Shekels" } } }, "localname": "ILS", "nsuri": "http://xbrl.sec.gov/currency/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r341", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cnbxpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r84", "r85", "r138", "r143", "r196", "r305", "r307" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r84", "r85", "r138", "r143", "r196", "r306", "r307" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r6" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities", "verboseLabel": "Accounts Payable and Accrued Liabilities, Current" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets", "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrentAndNoncurrent": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.", "label": "Accrued Salaries" } } }, "localname": "AccruedSalariesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r62", "r63", "r64", "r66", "r73", "r74", "r352" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r11", "r12", "r38", "r60", "r223", "r235", "r236" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r33", "r319", "r371" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r157", "r158", "r159", "r244", "r356", "r357", "r358", "r363", "r372" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments required to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r21", "r22", "r156" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share based payment" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r51", "r59", "r83", "r108", "r113", "r117", "r124", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r165", "r167", "r179", "r219", "r264", "r319", "r329", "r361", "r362", "r367" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r56", "r61", "r83", "r124", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r165", "r167", "r179", "r319", "r361", "r362", "r367" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r16", "r58", "r304" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r16", "r43", "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of the Period", "periodStartLabel": "Cash and cash equivalents at beginning of the Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r43" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r47", "r127", "r128", "r303", "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r320", "r321", "r322", "r324", "r325", "r326", "r327", "r356", "r357", "r363", "r370", "r372" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheetsParenthetical", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r32", "r252" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheetsParenthetical", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r32", "r252", "r270", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r32", "r221", "r319" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value, 900,000,000 shares authorized, 16,033,732 shares issued and outstanding at May 31, 2023 and 1,257,927 shares issued and outstanding at August 31, 2022." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r13", "r69", "r71", "r77", "r214", "r229" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive (income) loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r23", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible loan" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r17", "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r17", "r18" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r2", "r19" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r78", "r91", "r92", "r93", "r94", "r95", "r99", "r101", "r103", "r104", "r105", "r106", "r177", "r178", "r215", "r230", "r309" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r78", "r91", "r92", "r93", "r94", "r95", "r101", "r103", "r104", "r105", "r106", "r177", "r178", "r215", "r230", "r309" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r180" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate fluctuations on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r4", "r54", "r72", "r73", "r74", "r86", "r87", "r88", "r90", "r96", "r98", "r107", "r125", "r126", "r154", "r157", "r158", "r159", "r162", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r176", "r181", "r183", "r184", "r185", "r186", "r187", "r190", "r231", "r232", "r233", "r244", "r294" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r40", "r274" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r1" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r1" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Accounts Receivable and pre paid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r218" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Available for sale Investment" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r2" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Stock issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r37", "r52", "r225", "r319", "r355", "r359", "r364" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r57", "r83", "r124", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r166", "r167", "r168", "r179", "r319", "r361", "r367", "r368" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net cash gain in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r43", "r44", "r45" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r39", "r45", "r53", "r55", "r67", "r70", "r74", "r83", "r89", "r91", "r92", "r93", "r94", "r97", "r98", "r102", "r108", "r112", "r116", "r118", "r124", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r178", "r179", "r227", "r272", "r292", "r293", "r310", "r328", "r361" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Loss", "negatedLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative", "http://cnbxpharma.com/role/StatementsOfCashFlows", "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant non-cash transactions:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonmonetaryTransactionTypeAxis": { "auth_ref": [ "r188", "r189", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "label": "Nonmonetary Transaction Type [Axis]" } } }, "localname": "NonmonetaryTransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NonmonetaryTransactionTypeDomain": { "auth_ref": [ "r188", "r189", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "localname": "NonmonetaryTransactionTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r108", "r112", "r116", "r118", "r310" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r28", "r50", "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Nature of Business, Presentation and Going Concern" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r10", "r222" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Issuance of warrants" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r62", "r63", "r65" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Profit (loss) from available for sale assets" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r4", "r5", "r68", "r71", "r76", "r181", "r182", "r187", "r213", "r228", "r352", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other comprehensive gain" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income" } } }, "localname": "OtherIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Other Noncash Expense" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r41" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Financial Income (Loss)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "auth_ref": [ "r42" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of machinery and equipment.", "label": "Payments to Acquire Machinery and Equipment", "negatedLabel": "Acquisition of equipment" } } }, "localname": "PaymentsToAcquireMachineryAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r31", "r141" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r31", "r252" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheetsParenthetical", "http://cnbxpharma.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r31", "r141" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r31", "r252", "r270", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r31", "r220", "r319" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding." } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r351" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r15" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "verboseLabel": "Convertible loan" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r14", "r79", "r122", "r123" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from sale of available for sale investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r3", "r217", "r226", "r319" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r155", "r194", "r195", "r247", "r248", "r249", "r250", "r251", "r269", "r271", "r301" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r275", "r276", "r279" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r155", "r194", "r195", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r247", "r248", "r249", "r250", "r251", "r269", "r271", "r301", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r191", "r192", "r193", "r195", "r197", "r241", "r242", "r243", "r277", "r278", "r279", "r298", "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r27", "r161", "r369" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expense", "verboseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative", "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r34", "r49", "r224", "r234", "r236", "r240", "r253", "r319" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets", "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r54", "r86", "r87", "r88", "r90", "r96", "r98", "r125", "r126", "r157", "r158", "r159", "r162", "r163", "r169", "r171", "r172", "r174", "r176", "r231", "r233", "r244", "r372" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r75", "r83", "r109", "r110", "r111", "r114", "r115", "r119", "r120", "r121", "r124", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r179", "r216", "r361" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r24", "r25", "r275", "r276", "r279" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r1" ], "calculation": { "http://cnbxpharma.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Share based payment" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Beginning balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r4", "r9", "r54", "r72", "r73", "r74", "r86", "r87", "r88", "r90", "r96", "r98", "r107", "r125", "r126", "r154", "r157", "r158", "r159", "r162", "r163", "r169", "r170", "r171", "r172", "r173", "r174", "r176", "r181", "r183", "r184", "r185", "r186", "r187", "r190", "r231", "r232", "r233", "r244", "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r86", "r87", "r88", "r107", "r200", "r239", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r273", "r274", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r323" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r86", "r87", "r88", "r107", "r200", "r239", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r271", "r273", "r274", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r323" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r4", "r8", "r20", "r49", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Beginning balance, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r4", "r9", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Exercise of CLA to shares" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r32", "r35", "r36", "r46", "r254", "r270", "r295", "r296", "r319", "r329", "r355", "r359", "r364", "r372" ], "calculation": { "http://cnbxpharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets", "http://cnbxpharma.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r48", "r82", "r140", "r142", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r175", "r297", "r299", "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r198", "r199" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/NatureOfBusinessPresentationAndGoingConcernPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r100", "r105" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of shares outstanding - Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r99", "r105" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares outstanding - Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cnbxpharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482864/845-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482864/845-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r331": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r332": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r333": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r334": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r335": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r336": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r337": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r338": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r339": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r341": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r342": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r343": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r344": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r345": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r346": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r347": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r348": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r349": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 34 0001683168-23-004890-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-23-004890-xbrl.zip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�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end